Retrospective analysis of risk factors for thrombotic events due to the use of combined oral contraceptives


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Despite the improvement and widespread use of hormonal contraceptives, both one of the most reliable methods of contraception and a treatment for many gynecological diseases, various thrombotic events are still common and most dangerous side effects of these drugs. Objective. To provide a rationale for the need to study the hemostatic system in women taking hormonal contraceptives in order to prevent venous thromboembolism. Subjects and methods. A total of 56 reproductive-aged patients with thrombosis who received hormonal contraceptives were retrospectively analyzed. Results. The genetic and acquired forms of thrombophilia in patients with thrombosis who took combined oral contraceptives were analyzed. 75% of them were found to present with some forms of thrombophilia. 80.5% of all patients with genetic thrombophilia had a compromised family thrombotic history. Conclusion. The study of the hemostatic system before using combined oral contraceptives allows timely identification of women at high risk for thrombotic events.

Full Text

Restricted Access

About the authors

Nadina Moktarovna Khamani

I.M. Sechenov FMSU (Sechenov University)

Email: nadinka@list.ru
Researcher, Department of Obstetrics and Gynecology

Ravzat Abdulatipovna Saidova

I.M. Sechenov FMSU (Sechenov University)

Email: saidova.ra@gmail.com
MD, Professor, Department of Obstetrics and Gynecology

Inessa Vasilievna Khamani

I.M. Sechenov FMSU (Sechenov University)

Email: dr.hamani@list.ru
PhD, Associate Professor, Department of Obstetrics and Gynecology

Tamara Yakobovna Mashkova

I.M. Sechenov FMSU (Sechenov University)

Email: iza.62@mail.ru
Associate Professor, Department of Obstetrics and Gynecology

Elena Sergeevna Egorova

I.M. Sechenov FMSU (Sechenov University)

Email: eesdoctor@mail.ru
Associate Professor, Department of Obstetrics and Gynecology

I. S Kalashnikova

I.M. Sechenov First Moscow State Medical University (Sechenov University)

References

  1. Trenor С.С. 3rd, Chung R.J., Michelson AD., Neufeld E.J., Gordon C.M., Laufer M.R., Emans S.J. Hormonal contraception and thrombotic risk: a multidisciplinary approach. Pediatrics. 2011; 127(2): 347-57.
  2. Dhont М. History of hormonal contraception. Eur. J. Contracept. Reprod. Health Care. 2010; 15(Suppl. 2): 12-8.
  3. Макацария А.Д., Саидова Р.А. Гормональная контрацепция и тромбофилические состояния. M.: Триада-Х; 2004. 240с.
  4. Chen М., Culwell К. Contraception for women with medical problems. Glob. Libr. Women’s Med. 2015. https://doi.org/10.3843/GLQWM.10382.
  5. Lidegaard O., Edstrom B., Kreiner S. Qral contraceptives and venous thromboembolism: a five-year national case-control study. Contraception. 2002; 65(3): 187-96.
  6. Suchon P., AlFrouh F., Henneuse A., Ibrahim M., Brunet D., Barthet M.C. et al. Risk factors for venous thromboembolism in women under combined oral contraceptive. Thromb. Haemost. 2016; 115(1): 135-142.
  7. Hugon-Rodin J., Horellou M., Conard J., Gompel A., Plu-Bureau G. Combined hormonal contraceptives and first venous thrombosis in young french women: impact of thrombotic family history. J. Endocr. Soc. 2017; 1(6): 762-71. https:// doi.org/10.1210/js.2017-00090.
  8. Макарация А.Д., ред. Тромбогеморрагические осложнения в акушерско-гинекологической практике. Руководство для врачей. M.: МИА; 2011. 1050с.
  9. Gourdy Р., Bachelot А., Catteau-Jonard S., Christin-Maitre S., Conard J., Fredenrich A. et al. Hormonal contraception in women at risk of vascular and metabolic disorders: Guidelines of the French Society of Endocrinology. Ann. Endocrinol. (Paris). 2012; 73(5): 469-87.
  10. Rott H. Birth control pills and thrombotic risks: differences of contraception methods with and without estrogen. Hamostaseologie. 2019; 39(1): 42-8. https:// doi.org/10.1055/s-0039-1677806.
  11. Tans G., Vlieg H.A., Thomassen M.C., Curvers J., Bertina R.M., Rosing J. et al. Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women. Br. J. Haematol. 2003; 122(3): 465-70.
  12. Хамани Н.М. Особенности ведения беременности и родов у женщины с гомозиготной мутацией протромбина (Pt Thr165Met) и рецидивирующей ТЭЛА в анамнезе на фоне приема гормональной контрацепции. Акушерство, гинекология и репродукция. 2018; 12(1): 99-104.
  13. Макацария А.Д., Бицадзе В.О., Акиньшина С.В. Тромбозы и тромбоэмболии в акушерско-гинекологической клинике. M.: МИА; 2007. 1064с.
  14. Wiegratz I., Lee J.H., Kutschera E., Winkler U.H., Kuhl H. Effect of four oral contraceptives on hemostatic parameters. Contraception. 2004; 70(2): 97-106.
  15. Bergendal A., Persson I., Odeberg J., Sundstrom A., Holmstrom M., Schulman S. et al. Association of venous thromboembolism with hormonal contraception and thrombophilic genotypes. Qbstet. Gynecol. 2014; 124(3): 600-9.
  16. Макацария А.Д., Хизроева Д.Х., Бицадзе В.О., Акиньшина С.В. Беременность и гомозиготные и сочетанные формы тромофилии у пациенток с тромботическим и акушерским отягощённым анамнезом. Тромбоз, гемостаз и реология. 2016; Приложение 3: 269-70.
  17. Grimes D.A., Stuart G.S., Levi E.E. Screening women for oral contraception: can family history identify inherited thrombophilias? Qbstet. Gynecol. 2012; 120(4): 889-95.
  18. Jick H., Jick S.S., Gurewich V., Myers M.W., Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet. 1995; 346(8990): 1589-93.
  19. Vlieg H.A., Helmerhorst F.M., Vandenbroucke J.P, Doggen C.J.M., Rosendaal F.R. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ. 2009; 339: b2921, 10.1136/bmj.b2921.
  20. Lidegaard 0., Nielsen L.H., Skovlund C.W., Skjeldestad F.E., Lokkegaard E. (2011) Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study 2001-9. BMJ. 2011; 343: d6423.
  21. Dinger J., Assmann A., Mohner S. Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study. J. Fam. Plann. Reprod. Health Care. 2010; 36(3): 123-9.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2019 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies